Ultragenyx Pharmaceutical
RARE
172 hedge funds and large institutions have $2.51B invested in Ultragenyx Pharmaceutical in 2019 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 74 increasing their positions, 45 reducing their positions, and 22 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 45
23% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 22
1% more funds holding
Funds holding: 170 → 172 (+2)
0.69% less ownership
Funds ownership: 102.52% → 101.83% (-0.69%)
33% less capital invested
Capital invested by funds: $3.74B → $2.51B (-$1.23B)
60% less call options, than puts
Call options by funds: $3.13M | Put options by funds: $7.74M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$58.7M |
| 2 |
O
OrbiMed
New York
|
+$41M |
| 3 |
Capital World Investors
Los Angeles,
California
|
+$27.2M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$23.8M |
| 5 |
CII
Capital International Inc
Los Angeles,
California
|
+$21.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$175M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$28M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$23.7M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$19.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.3M |
RARE Hedge Fund Activity: Q3 2019 in Review
172 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2019, worth a combined $2.51B — down 33% from $3.74B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new RARE positions and 22 closed out — a net gain of 5 holders — while 74 added to existing stakes and 45 trimmed.
The largest buyer was Federated Hermes, adding an estimated $58.7M. The largest seller was Wellington Management Group, cutting an estimated $175M.
- 172 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2019, up from 170 in Q2 2019.
- Funds reported $2.51B of Ultragenyx Pharmaceutical stock for Q3 2019, down 33% quarter-over-quarter.
- 27 funds opened new Ultragenyx Pharmaceutical positions in Q3 2019 and 22 closed out, a net change of +5 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2019 was Federated Hermes, an estimated $58.7M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2019 was Wellington Management Group, an estimated $175M sold.
Based on aggregated 13F filings for Q3 2019.